Document is current
Any future updates will be listed below
-
Authors
Chao, Yvonne L.
Zhou, Katherine I. https://orcid.org/0000-0001-6442-0475
Forbes, Kwame K.
Porrello, Alessandro
Gentile, Gabrielle M. https://orcid.org/0000-0002-2669-1861
Zhu, Yinzhou https://orcid.org/0000-0003-0043-1321
Chack, Aaron C.
John Mary, Dixcy J. S. https://orcid.org/0000-0001-7788-2599
Liu, Haizhou
Cockman, Eric
Edatt, Lincy
Goda, Grant A.
Zhao, Justin J.
Abou Assi, Hala https://orcid.org/0000-0003-1087-8805
Wiedner, Hannah J.
Tsai, Yihsuan
Wilkinson, Lily
Van Swearingen, Amanda E. D.
Carey, Lisa A. https://orcid.org/0000-0003-2388-4649
Giudice, Jimena https://orcid.org/0000-0002-3330-7784
Dominguez, Daniel https://orcid.org/0000-0002-8630-2776
Holley, Christopher L. https://orcid.org/0000-0002-2870-3352
Pecot, Chad V. https://orcid.org/0000-0002-5250-2999
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA215075, R01CA258451, R01CA279532, 1R41CA246848, and 1R44CA284932)
- License Information
-
More Information
Article History
Received: 2 May 2023
Accepted: 22 April 2025
First Online: 2 May 2025
Competing interests
: C.V.P. is the founder of EnFuego Therapeutics, Inc., which is focused on the development of RNA-based therapeutics, and he holds equity in the company. C.L.H. is a co-founder of snoPanTher, which is focused on the development of snoRNA-targeted RNA therapeutics, and he holds equity in the company. The remaining authors disclose no potential conflicts of interest.
